Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Lymphoma
100%
Intensive Care Medicine
100%
Frontline Therapy
100%
Autotransplant
100%
Incomplete Response
100%
Complete Remission
85%
Allogeneic Bone Marrow Transplantation
71%
Hodgkin Disease
71%
Conventional Dose
57%
Event-free Survival
28%
Partial Response
28%
Melphalan
28%
Etoposide
28%
Induction Therapy
28%
Salvage Therapy
28%
Upfront Chemotherapy
28%
Overall Survival
14%
Patient Selection
14%
Poor Prognosis
14%
Salvage Chemotherapy
14%
Advanced Stage Disease
14%
Response Rate
14%
Prolonged Survival
14%
Anthracyclines
14%
Working Diagnosis
14%
Chemotherapy Regimen
14%
Salvage Treatment
14%
Blood Cells
14%
Overall Response Rate
14%
Bone Marrow Mononuclear Cells
14%
Involved Field Radiotherapy
14%
Bulky Disease
14%
Medicine and Dentistry
Intensive Care
100%
Hodgkin's Lymphoma
100%
Autograft
100%
Autologous Bone Marrow Transplantation
100%
Event Free Survival
60%
Salvage Therapy
40%
Etoposide
40%
Melphalan
40%
Overall Survival
20%
Infusion
20%
Anthracycline
20%
Adriamycin Bleomycin Vinblastine Dacarbazine
20%
Involved-Field Radiotherapy
20%
Chemotherapy
20%
Diseases
20%
Nursing and Health Professions
Intensive Care
100%
Remission
100%
Autograft
100%
Hodgkin Disease
83%
Autologous Bone Marrow Transplantation
83%
Event Free Survival
50%
Salvage Therapy
33%
Etoposide
33%
Melphalan
33%
Infusion
16%
Overall Survival
16%
Anthracycline
16%
Diseases
16%
Radiotherapy
16%
Pharmacology, Toxicology and Pharmaceutical Science
Remission
100%
Hodgkin Disease
83%
Chemotherapy
50%
Event Free Survival
50%
Etoposide
33%
Melphalan
33%
Overall Survival
16%
Anthracycline
16%
Diseases
16%